57962-014 : Imbruvica 140 mg Oral Tablet, Film Coated
NDC: | 57962-014 |
Labeler: | Pharmacyclics LLC |
Product Type: | Human Prescription Drug |
Drug Name: | Imbruvica |
Dosage Form: | Oral Tablet, Film Coated |
Application #: | NDA210563 |
Rev. Date: |
Appearance:
Markings: | ibr;140 |
Shapes: |
Round |
Colors: |
Green |
Size (mm): | 9 |
Segments: * | 1 |
* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines. |
NDC Package Codes:
- 57962-014-28: 1 BLISTER PACK IN 1 CARTON (57962‑014‑28) > 28 TABLET, FILM COATED IN 1 BLISTER PACK
Active Ingredients:
- Ibrutinib
Dosage Strength:
- 140 mg
Pharmaceutical Classes:
- Kinase Inhibitor [EPC]
- Protein Kinase Inhibitors [MoA]
Related Products:
Based on records with the same trade name.- 57962-007 Imbruvica 70 mg/ml Oral Suspension by Pharmacyclics LLC
- 57962-070 Imbruvica 70 mg Oral Capsule by Pharmacyclics LLC
- 57962-280 Imbruvica 280 mg Oral Tablet, Film Coated by Pharmacyclics LLC
- 57962-420 Imbruvica 420 mg Oral Tablet, Film Coated by Pharmacyclics LLC
- 57962-560 Imbruvica 560 mg Oral Tablet, Film Coated by Pharmacyclics LLC
- 57962-140 Imbruvica (Ibrutinib 140 mg) by Pharmacyclics, Inc
NDC QR Code
Scan the QR code below to easily reference this data in the future:< Prev: 57962-007Next: 57962-070 >
Related Discussions:
side effects with imbruvica
I have CLL/SLL with 11q deletion, recently I have been having several problems and cannot find the right information on ... 4 replies
I have CLL/SLL with 11q deletion, recently I have been having several problems and cannot find the right information on ... 4 replies
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.